Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Atika Capital Management LLC

Atika Capital Management LLC lessened its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 33.8% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 477,000 shares of the company’s stock after selling 243,000 shares during the quarter. Teva Pharmaceutical Industries accounts for approximately 1.8% of Atika Capital Management LLC’s portfolio, making the stock its 12th biggest position. Atika Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $14,367,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of TEVA. Norges Bank purchased a new position in Teva Pharmaceutical Industries during the 4th quarter valued at about $1,098,060,000. WCM Investment Management LLC increased its stake in Teva Pharmaceutical Industries by 191.4% during the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after purchasing an additional 26,813,522 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 19.2% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock valued at $1,402,945,000 after purchasing an additional 7,255,083 shares during the period. Wellington Management Group LLP boosted its position in Teva Pharmaceutical Industries by 39,228.4% in the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock valued at $139,296,000 after buying an additional 6,878,304 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd boosted its position in Teva Pharmaceutical Industries by 18.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock valued at $1,171,378,000 after buying an additional 5,917,423 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Activity

In related news, CAO Amir Weiss sold 10,679 shares of the stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total transaction of $384,444.00. Following the completion of the sale, the chief accounting officer owned 20,016 shares in the company, valued at $720,576. This represents a 34.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Richard Daniell sold 30,000 shares of the stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the sale, the executive vice president owned 55,755 shares of the company’s stock, valued at $1,973,727. This trade represents a 34.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 465,931 shares of company stock worth $16,332,989 over the last ninety days. 0.54% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $31.16 on Friday. The stock has a 50 day moving average price of $33.36 and a 200 day moving average price of $32.69. Teva Pharmaceutical Industries Ltd. has a 52-week low of $14.99 and a 52-week high of $37.35. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. The company has a market capitalization of $35.82 billion, a price-to-earnings ratio of 23.43, a price-to-earnings-growth ratio of 3.18 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The company had revenue of $3.98 billion for the quarter. Research analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TEVA has been the topic of a number of recent research reports. UBS Group upped their price objective on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Truist Financial lifted their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Barclays boosted their target price on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Piper Sandler restated an “overweight” rating and set a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Finally, Bank of America upped their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $41.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.